Iberdomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II drugs for Follicular Lymphoma have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Iberdomide hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Iberdomide hydrochloride overview
Iberdomide hydrochloride (CC-220) is under development for the treatment of systemic lupus erythematosus, relapsed/refractory multiple myeloma, aggressive B-cell lymphoma, B-cell lymphoma, unspecified B-cell lymphomas, T-cell lymphoma, natural killer (NK)-cell non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), marginal zone lymphoma (MZL), extranodal marginal zone b-cell lymphoma (mucosa-associated lymphoid tissue or malt-lymphoma, nodal marginal zone b-cell lymphoma, splenic marginal zone b-cell lymphoma, mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL), Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma, and classical Hodgkin lymphoma (CHL). The drug candidate is administered orally. It targets cereblon (CRBN) and inhibits CRBN ubiquitination. The drug candidate is an immunomodulatory imide drug (IMiD). It was also under development for cutaneous lupus erythematosus, systemic sclerosis and chronic cutaneous sarcoidosis.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
For a complete picture of Iberdomide hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.